VanEck Vectors Biotech ETF (BBH)
| Assets | $627.45M |
| NAV | $218.51 |
| Expense Ratio | 0.35% |
| PE Ratio | 31.66 |
| Shares Out | 2.87M |
| Dividend (ttm) | $0.61 |
| Dividend Yield | 0.28% |
| Ex-Dividend Date | Dec 21, 2020 |
| 1-Year Return | - |
| Volume | 29,846 |
| Open | 214.19 |
| Previous Close | 214.61 |
| Day's Range | 207.93 - 214.19 |
| 52-Week Low | 150.00 |
| 52-Week High | 222.22 |
| Beta | 0.90 |
| Holdings | 26 |
| Inception Date | Dec 20, 2011 |
About BBH
The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Top 10 Holdings
58.69% of assets| Name | Symbol | Weight |
|---|---|---|
| Moderna | MRNA | 12.07% |
| Amgen | AMGN | 7.78% |
| Gilead Sciences | GILD | 5.33% |
| IQVIA Holdings | IQV | 5.05% |
| ICON plc | ICLR | 4.96% |
| Vertex Pharmaceuticals | VRTX | 4.85% |
| Regeneron Pharmaceuticals | REGN | 4.83% |
| Illumina | ILMN | 4.73% |
| Biogen | BIIB | 4.59% |
| BioNTech SE | BNTX | 4.51% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 21, 2020 | $0.6079 | Dec 28, 2020 |
| Dec 23, 2019 | $0.4724 | Dec 30, 2019 |
| Dec 20, 2018 | $0.551 | Dec 27, 2018 |
| Dec 18, 2017 | $0.683 | Dec 22, 2017 |
| Dec 19, 2016 | $0.327 | Dec 23, 2016 |
| Dec 21, 2015 | $0.337 | Dec 28, 2015 |
News
Biotech Stocks Have Colds, but They Can Heal
This year hasn't been kind to biotechnology stocks and related exchange traded funds. The headwinds faced by these assets were ratcheted up last week when the Biden administration revealed plans to purs...
Mostly Sanguine Regulatory Outlook for Biotech, Healthcare Names
A change in leadership in the Oval Office often stirs talk about the regulatory environment for the healthcare sector. That talk is often elevated when one party controls the presidency and both houses ...
Time for Pharma and Healthcare ETFs?
The broader medical sector should gain on decent earnings expectations and higher COVID-19-related sales
Changing FDA Regulatory Environment Could Bolster Biotech, ‘BBH'
The Food & Drug Administration's (FDA) recent green light of Biogen's Alzheimer's disease drug Aducanumab – the first new Alzheimer's approval in roughly two decades – could be a sign the FDA is taking ...
Will Biotech ETFs Benefit from Biogen's New Alzheimer's Drug?
Biotech investors may have reason to celebrate this week, as the FDA approved Biogen's Alzheimer's disease drug Aducanumab on Monday, ushering in the first medication to be allowed by U.S. regulators to...
Biotech ETFs to Suffer as US Backs IP Waiver for COVID-19 Vaccines
The Biden administration recently informed about supporting the waiver of intellectual property protections for COVID-19 vaccines that has been proposed by South Africa and India.
How Will Biotech ETFs React to These Q1 Earnings Releases?
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Biotech ETFs Make Gains Tuesday, Despite the J&J Vaccine Pause
Some biotech and pharmaceutical ETFs are gaining on Tuesday despite news that Johnson and Johnson's coronavirus vaccine has been halted in over two dozen states, after the Food and Drug Administration r...
Biotech Shined with Vaccines. It Can Do It Again with ‘BBH'
The United States and China have been locking horns when it comes to technological advances. ETF investors looking to capitalize on strength in U.S. biotech should give the VanEck Vectors® Biotech ETF (...
10 ETFs to Buy to Mimic 2021's Best Stock Picks
Investors looking to reduce the risk of owning some of 2021's best stocks might consider these 10 ETFs to buy instead. The post 10 ETFs to Buy to Mimic 2021's Best Stock Picks appeared first on Investor...
Illumina Earnings, Forward Guidance Strengthen Biotech ETFs
Biotechnology sector-related exchange traded funds strengthened after Illumina (NasdaqGS: ILMN) announced better-than-expected quarterly earnings and an optimistic 2021 outlook. On Friday, the VanEck Ve...
IPOs Are Back. Get In On the Action with the BBH ETF
2020 saw a lot of initial public offerings (IPOs) put on hold thanks to Covid-19. Now that a global vaccine rollout is underway, biotech IPOs are hitting the markets and boosting the VanEck Vectors® Bio...
How Will Biotech ETFs React to These Q4 Earnings Releases?
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry post their fourth-quarter earnings releases amid the coronavirus crisis.